Recent advances in antiviral drugs for Chikungunya virus (CHIKV): Targets, mechanisms, and development strategies
Acta Pharmaceutica Sinica B · 2026-06 · 16 (6) · 3257-3291
DOI: 10.1016/j.apsb.2026.03.044 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-06. Verfasst von Xiaowen Jiang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 215 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Department of Education of Liaoning Province.
Abstract (Originalsprache)
Chikungunya virus (CHIKV), an alphavirus transmitted by Aedes mosquitoes, has frequently caused outbreaks in tropical and subtropical regions worldwide, posing a significant public health threat. CHIKV infection leads to chikungunya fever, characterized by fever, rash, and persistent joint pain, with approximately 30%-40% of patients developing chronic arthritis that severely impacts quality of life. Currently, no specific antiviral drugs or vaccines against CHIKV have been approved for clinical use, highlighting the urgency of drug development. This review systematically summarizes recent progress in antiviral research on CHIKV, focusing on key target proteins in the viral life cycle, such as non-structural proteins nsP1, nsP2, nsP3, nsP4, and structural protein E1-E2 complexes, as well as the mechanisms of action of their inhibitors. We analyze the current research status of various anti-CHIKV compounds, including suramin, baicalin, halofuginone, betulinic acid, andrographolide, and itraconazole. Additionally, we summarize host-directed antiviral strategies targeting pathways such as host cell oxidative folding, Na+/K+-ATPase, and MAPK signaling. This review aims to establish a theoretical foundation and outline potential research directions for the development of CHIKV-related therapeutics, thereby facilitating the discovery of effective treatment strategies against this pathogen.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China.
- Key Laboratory of Pharmacodynamic Substances Research & Translational Medicine of Immune Diseases, Shenyang Pharmaceutical University, Shenyang 110016, China.
- Department of Clinical Pharmacology, China Medical University, Shenyang 110112, China.
- School of Functional Foods and Wine, Shenyang Pharmaceutical University, Shenyang 110016, China.
Förderung
- Department of Education of Liaoning Province
Zitieren
APA
Jiang, X., Zhao, Y., Lu, H., Li, K., & Gao, H. (2026). Recent advances in antiviral drugs for Chikungunya virus (CHIKV): Targets, mechanisms, and development strategies. Acta Pharmaceutica Sinica B, 16(6), 3257-3291. https://doi.org/10.1016/j.apsb.2026.03.044
Vancouver
Jiang X, Zhao Y, Lu H, Li K, Gao H. Recent advances in antiviral drugs for Chikungunya virus (CHIKV): Targets, mechanisms, and development strategies. Acta Pharmaceutica Sinica B. 2026;16(6):3257-3291. doi:10.1016/j.apsb.2026.03.044
BibTeX
@article{Jiang2026,
author = {Jiang, Xiaowen and Zhao, Yudan and Lu, Hongyuan and Li, Keqiang and Gao, Huiyuan},
title = {Recent advances in antiviral drugs for Chikungunya virus (CHIKV): Targets, mechanisms, and development strategies},
journal = {Acta Pharmaceutica Sinica B},
year = {2026},
volume = {16},
number = {6},
pages = {3257--3291},
doi = {10.1016/j.apsb.2026.03.044}
}
EUVIMED